Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01946074 · ClinicalTrials.gov registry record · Phase 1
A Study of ABT-165 in Subjects With Solid Tumors
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 101
- Enrollment target
NCT01946074 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 101 participants.
The verdict
NCT01946074, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 101 participants
- Enrollment target
Study Summary
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-165 when administered as monotherapy and in combination with paclitaxel or 5-fluoruracil, folinic acid and irinotecan (FOLFIRI) or ABBV-181 with/without paclitaxel in subjects with advanced solid tumors. Enrollment to Cohorts A, B were completed and for Cohorts C and D are recruiting.
Interventions
- DRUG FOLFIRI
- DRUG paclitaxel
- DRUG ABBV-181
- DRUG ABT-165
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2013-08-08 |
| Est. Completion | 2022-09-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01946074
The ClinicalTrials.gov registry entry for NCT01946074 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which FOLFIRI is the first listed.
NCT01946074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01946074 about?
NCT01946074 is a clinical study titled "A Study of ABT-165 in Subjects With Solid Tumors". This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-165 when administered as monotherapy and in combination with paclitaxel or 5-fluoruracil, folinic acid and irinotecan (FOLFIRI) or ABBV-181 with/without paclitaxel in subjects with adv...
What is the current status of trial NCT01946074?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 101 participants. The study started on 2013-08-08. Estimated completion is 2022-09-28.
What interventions are being tested in trial NCT01946074?
The interventions under investigation include: FOLFIRI (DRUG), paclitaxel (DRUG), ABBV-181 (DRUG), ABT-165 (DRUG).
Who is sponsoring clinical trial NCT01946074?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.